RetroSense Therapeutics secures $6 million in Series A financing

RetroSense Therapeutics has secured $6 million in Series A financing to investigate the use of gene therapy and optogenetics to restore vision loss, according to a press release.Proceeds from the financing may enable completion of preclinical studies needed to support an investigation new drug filing with the U.S. Food and Drug Administration for RST-001, a treatment for retinitis pigmentosa, according to the release. The IND filing is expected early this year.